ERBB2 and breast cancer: As for molecular subtype, nine patients (42.8%) presented with Luminal A-like BC, two (9.5%) with Luminal B-like HER2-negative BC, five (23.8%) with Luminal B-like HER2-positive BC, one (4.8%) with HER2 enriched-like BC, and four (19%) with triple-negative BC.